Benzinga | Dec 15, 2021 05:17AM EST

Stifel Downgrades Adagio Therapeutics to Hold, Lowers Price Target to $9

Stifel analyst Stephen Willey downgrades Adagio Therapeutics (NASDAQ:ADGI) from Buy to Hold and lowers the price target from $50 to $9.